Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ESG
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Sep 08, 2015 7:30am EDT

Rigel Granted Orphan Drug Designation for Fostamatinib in ITP

Aug 04, 2015 4:05pm EDT

Rigel Announces Second Quarter 2015 Financial Results

Jul 28, 2015 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results

Jun 30, 2015 7:30am EDT

Rigel Welcomes Keith A. Katkin to Board of Directors

May 28, 2015 7:30am EDT

Rigel to Present at Jefferies 2015 Global Healthcare Conference

May 07, 2015 4:05pm EDT

Rigel Announces First Quarter 2015 Financial Results

Mar 03, 2015 7:30am EST

Rigel Announces Fourth Quarter and Year End 2014 Financial Results

Feb 23, 2015 8:03am EST

Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications

Jan 08, 2015 7:30am EST

Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Nov 24, 2014 7:30am EST

Rigel Announces Executive Management Changes

  • Previous
  • 1…
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • …41
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin